Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

FTSE 100 ends week lower after week AstraZeneca, RBS results

share with twitter share with LinkedIn share with facebook
share via e-mail
02/14/2020 | 12:30pm EST
FILE PHOTO: The London Stock Exchange Group offices are seen in the City of London, Britain

UK blue-chip shares fell for a second day on Friday after AstraZeneca and RBS reported underwhelming results, while investors remained unsettled because of concerns over the impact of the coronavirus outbreak on the global economy.

The FTSE 100 index ended the Valentine's Day trading session 0.6% lower, down 0.8% for the week, while the midcap bourse rose 0.5% as it drew strength from the pound.

Global markets are expecting stimulus from central banks as new coronavirus showed no signs of peaking. U.S. Federal Reserve Chair Jerome Powell had last week warned that the economic impact from the outbreak could spill over globally.

The FTSE 100, with its larger exposure to commodity prices, has lagged its European counterpart, which has hovered at record high levels for most of the week, as investors shrugged off fears over the new virus.

London's main index has also been derailed as commodity prices take a hit from slower demand from China post the health crisis.

Among corporate news, AstraZeneca dropped over 4.3% as its quarterly earnings failed to match up to market expectations.

"Corporate updates triggered the declines in the pharma sector as well as the banking industry. Dealers are still worried about the health emergency in China as the situation isn't showing any signs of improving," CMC Markets analyst David Madden, said.

Royal Bank of Scotland fell 6.8%, ending the day at the bottom of the bluechip index, after its new top boss set out a new strategy that included cutting back the size of its loss-making investment bank and renaming the company NatWest.

"Every rose has its thorn; scratch beneath every RBS quarterly update and you'll find a sting or two," Markets.com analyst Neil Wilson wrote in note.

Warehousing specialist Segro outperformed the index, rising 1.5% and hitting a fresh high after it reported a jump in full-year profit and increased its dividend.

Among smaller stocks, biotechnology company Novacyt jumped 29% after it said it would launch a certified test for the new coronavirus next week.

Mosman Oil and Gas tanked 36% after it announced capital raise and updated the markets on its corporate strategy, which included the sale of some of its projects.

By Muvija M and Shashwat Awasthi

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.53% 7690 Delayed Quote.1.09%
CMC MARKETS PLC 1.34% 165.8 Delayed Quote.13.10%
FTSE 100 INDEX 0.28% 7234.11 End-of-day quote.0.00%
LONDON BRENT OIL -1.13% 58.45 Delayed Quote.-10.42%
MOSMAN OIL AND GAS LIMITED 0.00% 0.145 Delayed Quote.-36.96%
NOVACYT 84.55% 1.29 Real-time Quote.663.31%
SEGRO PLC 0.15% 921.4 Delayed Quote.2.70%
THE ROYAL BANK OF SCOTLAND GROUP PLC -1.73% 204.1 Delayed Quote.-15.06%
THORN GROUP LIMITED -2.56% 0.19 End-of-day quote.-7.14%
WTI -0.28% 53.31 Delayed Quote.-12.39%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
02/20EXCLUSIVE : Canadian regulator considers changes to new drug pricing plan
02/18Consumer groups, unions oppose fix for planned merger of AbbVie and Allergan
02/17ASTRAZENECA PLC : - Full-year and Q4 2019 results
02/14Health Care Flat Amid Mixed Earnings Season -- Health Care Roundup
02/14EUROPE : European shares settle below record highs
02/14FTSE 100 ends week lower after week AstraZeneca, RBS results
02/14NEWS HIGHLIGHTS : Top Company News of the Day
02/14GLOBAL MARKETS LIVE: Facebook ready to pay more taxes, Amazon gets JEDI suspe..
02/14AstraZeneca's CEO reaffirms 2021 targets
02/14AstraZeneca braces for coronavirus hit, but no impact so far
More news
Financials (USD)
Sales 2020 27 106 M
EBIT 2020 7 449 M
Net income 2020 3 013 M
Debt 2020 13 206 M
Yield 2020 2,86%
P/E ratio 2020 40,4x
P/E ratio 2021 27,4x
EV / Sales2020 5,31x
EV / Sales2021 4,77x
Capitalization 131 B
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 107,31  $
Last Close Price 99,69  $
Spread / Highest target 38,9%
Spread / Average Target 7,64%
Spread / Lowest Target -25,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679